JOURNAL ARTICLE
REVIEW
Add like
Add dislike
Add to saved papers

[Cetuximab].

Cetuximab, an IgG1 chimeric monoclonal antibody directed against the epidermal growth factor receptor (EGFR), has been shown to have antitumor activity against EGFR-expressing colorectal cancer (CRC). Although the activity of cetuximab monotherapy is notable,cetuximab-based combinations have conferred greater benefit, with two-fold higher response rates and nearly three-fold longer progression free-survival with cetuximab plus irinotecan compared with cetuximab alone,even in irinotecan-refractory patients. Cetuximab monotherapy should be reserved for patients who cannot tolerate combination therapy. Interestingly, consistent with other reports of both EGFR-targeting antibodies and receptor tyrosine kinase inhibitors, the severity of the rash related strongly to both response and survival. This hypothesis was tested in the EVEREST trial, in which patients with irinotecanrefractory CRC are randomly assigned to treatment with irinotecan plus cetuximab on either a conventional dose-schedule or titrated to a maximal-tolerated rash. By increasing cetuximab doses,a slightly higher skin reaction and response rate could be induced in the experimental arm. On the other hand,important phase III trials will present results in the near future (CRYSTAL and CALGB/SWOG 80405 trial). It remains to be seen if those trials can validate the encouraging data about cetuximab in the first-line treatment.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app